The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia

BACKGROUND: Elevated serum fibroblast growth factor 23 (FGF23) is strongly associated with cardiovascular risk and mortality. Tenapanor, an inhibitor of gastrointestinal sodium/hydrogen exchanger isoform 3, decreased serum phosphate in a randomized, double-blind, placebo-controlled Phase 2 trial (Cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Block, Geoffrey A, Rosenbaum, David P, Yan, Andrew, Greasley, Peter J, Chertow, Glenn M, Wolf, Myles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365767/
https://www.ncbi.nlm.nih.gov/pubmed/29617976
http://dx.doi.org/10.1093/ndt/gfy061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365767/
https://www.ncbi.nlm.nih.gov/pubmed/29617976
http://dx.doi.org/10.1093/ndt/gfy061

Ejemplares similares